It is in collaboration with the brand of breast prostheses, Boost. The two like-minded brands, whose products both boost the mood and confidence of women who have had breast surgery, will join forces at egg & co from April 5-17.
LoveRose is the UK’s first luxury lingerie collection created for women who have had breast cancer surgery. It combines the complex postoperative needs of women with luxurious design, high quality fabrics and matching clothing.
After founding their online business, appearing in egg & co, a space supporting women-led brands, presents the perfect opportunity for LoveRose founders Caroline Kennedy Alexander and Sarah Bell Jones to meet face-to-face with their customers after they appeared in the Den last month.
Cornwall-based Boost manufactures innovative and contemporary breast forms that challenge the assumption that a breast form should mimic skin tone. Their breast forms are available in a range of stylish colors to celebrate the healing, festive and expressive qualities of color.
LoveRose Lingerie is named after Alexander’s sister, Rose, one of two sisters who died of cancer.
Alexander studied fashion and founded and ran an international art gallery in Edinburgh for seven years before teaming up with fellow designer Sarah Bell Jones to create locally made bras, pants, dresses and suspenders. from durable fabrics and finished with silk.
She said: “I was blown away by the Dragons reaction to LoveRose and was overwhelmed by the support we have received since the show.
“Even though we haven’t secured any investment in the Den, it’s a really exciting time for us. We’re in conversation with new investors and, through our collaboration with Boost and pop up in egg & co, aim to continue to inspire women who have faced breast cancer.
The company initially raised a five-figure sum in a Kickstarter crowdfunding campaign to help get the business off the ground and went on to win the 2018 Scottish Edge Awards.
One in seven women in the UK will be diagnosed with breast cancer in their lifetime, with more than 500,000 women currently living well after treatment.
